PL3609486T3 - Sarpogrelat do zastosowania w sposobie leczenia choroby serca u ssaków - Google Patents

Sarpogrelat do zastosowania w sposobie leczenia choroby serca u ssaków

Info

Publication number
PL3609486T3
PL3609486T3 PL18716625T PL18716625T PL3609486T3 PL 3609486 T3 PL3609486 T3 PL 3609486T3 PL 18716625 T PL18716625 T PL 18716625T PL 18716625 T PL18716625 T PL 18716625T PL 3609486 T3 PL3609486 T3 PL 3609486T3
Authority
PL
Poland
Prior art keywords
sarpogrelate
mammals
treatment
heart disease
heart
Prior art date
Application number
PL18716625T
Other languages
English (en)
Inventor
Estelle AYME-DIETRICH
Jérôme GUYONNET
Roland LAWSON
Luc Maroteaux
Laurent MONASSIER
Original Assignee
Ceva Santé Animale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceva Santé Animale filed Critical Ceva Santé Animale
Publication of PL3609486T3 publication Critical patent/PL3609486T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18716625T 2017-04-11 2018-04-11 Sarpogrelat do zastosowania w sposobie leczenia choroby serca u ssaków PL3609486T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17165863 2017-04-11
EP17180011 2017-07-06
EP18716625.1A EP3609486B1 (en) 2017-04-11 2018-04-11 Sarpogrelate for use in a method for the treatment of heart disease in mammals
PCT/EP2018/059295 WO2018189246A1 (en) 2017-04-11 2018-04-11 Method for the treatment of heart disease in mammals

Publications (1)

Publication Number Publication Date
PL3609486T3 true PL3609486T3 (pl) 2021-11-29

Family

ID=61913190

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18716625T PL3609486T3 (pl) 2017-04-11 2018-04-11 Sarpogrelat do zastosowania w sposobie leczenia choroby serca u ssaków

Country Status (13)

Country Link
US (1) US11116741B2 (pl)
EP (1) EP3609486B1 (pl)
JP (1) JP7148545B2 (pl)
CN (1) CN110913846B (pl)
AU (1) AU2018253371B2 (pl)
BR (1) BR112019021344A2 (pl)
CA (1) CA3059512A1 (pl)
DK (1) DK3609486T3 (pl)
ES (1) ES2886045T3 (pl)
HU (1) HUE055319T2 (pl)
LT (1) LT3609486T (pl)
PL (1) PL3609486T3 (pl)
WO (1) WO2018189246A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102707874B1 (ko) * 2021-10-27 2024-09-25 주식회사 메디테이크 안지오텐신 수용체 차단제 및 sglt2 억제제를 포함하는 복합 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1951253A2 (en) * 2005-10-26 2008-08-06 Cotherix, Inc. Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
CN101234101A (zh) * 2007-02-02 2008-08-06 田边三菱制药株式会社 预防和/或治疗肥胖症的药物
GB0715047D0 (en) * 2007-08-02 2007-09-12 Glaxo Group Ltd Novel Compounds
US9808529B2 (en) * 2012-05-18 2017-11-07 Luoda Pharma Pty Ltd Liquid formulation
BR112015014964A2 (pt) * 2012-12-21 2017-07-11 Map Pharmaceuticals Inc novos derivados de metisergida
WO2016121738A1 (ja) * 2015-01-27 2016-08-04 国立大学法人山梨大学 シロスタゾールの薬効評価方法

Also Published As

Publication number Publication date
AU2018253371A1 (en) 2019-10-31
EP3609486A1 (en) 2020-02-19
CN110913846B (zh) 2023-04-04
AU2018253371B2 (en) 2023-10-19
US20200297685A1 (en) 2020-09-24
ES2886045T3 (es) 2021-12-16
CA3059512A1 (en) 2018-10-18
US11116741B2 (en) 2021-09-14
DK3609486T3 (da) 2021-08-16
CN110913846A (zh) 2020-03-24
LT3609486T (lt) 2021-10-11
WO2018189246A1 (en) 2018-10-18
JP7148545B2 (ja) 2022-10-05
BR112019021344A2 (pt) 2020-06-16
HUE055319T2 (hu) 2021-11-29
EP3609486B1 (en) 2021-06-02
JP2020513028A (ja) 2020-04-30

Similar Documents

Publication Publication Date Title
CA193739S (en) Skin massager
CA196432S (en) Skin massager
CA193621S (en) Skin massager
IL272300A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
IL256175A (en) Using exosomes to treat the disease
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
HUE059752T2 (hu) A danon betegség és az autofágia egyéb rendellenességeinek kezelésére szolgáló módszerek
PT3600415T (pt) Anticorpo contra recetor de activina do recetor do tipo ii para utilização no tratamento de insuficiência cardíaca
IL254496A0 (en) Treatment of type 2 diabetes patients
IL254500A0 (en) Treatment of patients with type 2 diabetes
PL3484475T3 (pl) 1-Metylonikotynamid do leczenia choroby układu krążenia
SG11202010802PA (en) Treatment plan facilitator
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
PL3609486T3 (pl) Sarpogrelat do zastosowania w sposobie leczenia choroby serca u ssaków
GB2575031B (en) Skin treatment apparatus
IL273563A (en) A physiological compound for use in the treatment of osteoarthritic pain
IL272422A (en) Methods for treating diseases of the meninges
PL3710043T3 (pl) Fgf10 do leczenia chorób serca
PT3609486T (pt) Sarpogrelato para uso num método para o tratamento de doença cardíaca em mamíferos
IL246608A0 (en) Preparations and methods for treating heart disease
IL268265B (en) 3-beta-hydroxy-5-alpha-paragnane-20-one for use in medical treatment
GB201819776D0 (en) Medical process
GB201811912D0 (en) Treatment of disease
GB201811911D0 (en) Treatment of disease
GB201810974D0 (en) Treatment of disease